Prometheus Biosciences, Inc., (RXDX) Social Stream
PROMETHEUS BIOSCIENCES INC (RXDX) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering RXDX.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-02 | 3 | $40 | $34 | $36.333 | $114.47 | -68.26% |
| 2021-11-15 | 4 | $45 | $34 | $38.5 | $114.47 | -66.37% |
| 2021-12-08 | 5 | $50 | $40 | $44.8 | $114.47 | -60.86% |
| 2022-01-13 | 6 | $50 | $40 | $45 | $114.47 | -60.69% |
| 2022-02-11 | 7 | $62 | $40 | $47.428 | $114.47 | -58.57% |
| 2022-03-10 | 7 | $62 | $40 | $48.571 | $114.47 | -57.57% |
| 2022-05-12 | 5 | $62 | $42 | $50 | $114.47 | -56.32% |
| 2022-05-17 | 8 | $62 | $42 | $50 | $114.47 | -56.32% |
| 2022-06-10 | 8 | $62 | $42 | $50.375 | $114.47 | -55.99% |
| 2022-07-26 | 9 | $62 | $42 | $50.444 | $114.47 | -55.93% |
| 2022-08-11 | 9 | $62 | $42 | $50.888 | $114.47 | -55.54% |
| 2022-08-12 | 9 | $62 | $42 | $53.777 | $114.47 | -53.02% |
| 2022-08-29 | 9 | $71 | $50 | $58.555 | $114.47 | -48.85% |
| 2022-10-03 | 9 | $74 | $50 | $59.888 | $114.47 | -47.68% |
| 2022-10-20 | 9 | $74 | $50 | $62.111 | $114.47 | -45.74% |
| 2022-11-01 | 9 | $74 | $51 | $62.666 | $114.47 | -45.26% |
| 2022-11-10 | 9 | $74 | $51 | $62.555 | $114.47 | -45.35% |
| 2022-12-08 | 9 | $185 | $51 | $117.1 | $114.47 | 2.3% |
| 2022-12-11 | 9 | $185 | $51 | $127.1 | $114.47 | 11.03% |
| 2022-12-16 | 9 | $185 | $51 | $137.1 | $114.47 | 19.77% |
The Trend in the Analyst Price Target
RXDX's average price target has moved up $92.1 over the prior 48 weeks.
Over the past 44 weeks, RXDX's average upside potential has been 32.92%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-03-10 | 7 | 62 | 40 | 48.571 | 50.00 | -2.86% |
| 2022-03-10 | 5 | 62 | 42 | 50.000 | 50.00 | 0% |
| 2022-05-12 | 7 | 62 | 42 | 50.000 | 23.57 | 112.13% |
| 2022-10-20 | 9 | 74 | 50 | 62.111 | 48.72 | 27.49% |
| 2022-12-08 | 9 | 185 | 51 | 117.100 | 117.21 | -0.09% |
RXDX Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.11 | 8 | 1 | 0 | 0 | 0 | 9 |
The Trend in the Broker Recommendations
RXDX's average broker recommendation rating improved by 0.03 over the prior 48 weeks.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In the context of all US stocks, PROMETHEUS BIOSCIENCES INC's upside potential (average analyst target price relative to current price) is higher than 93.69% of them.
- In terms of how PROMETHEUS BIOSCIENCES INC fares relative to Pharmaceutical Products stocks, note that its variance in analysts' estimates is lower than -627.86% of that group.
- In the context of Pharmaceutical Products stocks, PROMETHEUS BIOSCIENCES INC's average analyst price target is higher than 1909.72% of them.
- RXDX has a greater number of analysts covering the stock than 1279.62% of stocks in the mid market cap category.
Stocks similar to PROMETHEUS BIOSCIENCES INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are EQRX, VALN, and OGN.
View All Top Stocks by Price Target
Make investment decisions regarding RXDX using the data that counts. Try POWR Ratings for free.